Clinical trials
Human Immunodeficiency Virus (HIV) Infection clinical trials
Below are recruiting human immunodeficiency virus (hiv) infection clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07209917Recruiting
Cervical cancer prevention for women with HIV and HPV
This trial tests a new way to prevent cervical cancer in women with both HIV and HPV. It focuses on women in India who are already on stable HIV treatment and have a normal cervical exam.
Bangalore, KarnatakaAges 25–50 - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT04375800RecruitingPhase 2
Doravirine for children with HIV infection and stable treatment
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
Aurora, ColoradoAges 4 weeks–11 years - NCT04430257Recruiting
PrEP for people at higher risk of HIV
This study checks whether taking HIV prevention medicine called PrEP can help protect people who are not living with HIV but have recent risk of HIV exposure. You may qualify if you have ongoing risk and are not already taking PrEP.
Cambridge, MassachusettsAges 18 years+ - NCT04760574Recruiting
HIV status and low testosterone in men
This study looks at whether low testosterone (often called male hypogonadism) is linked to having HIV. It compares HIV-positive men with HIV-negative men to better understand what contributes to hormone problems and how common they are.
TaipeiAges 20 years+ - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Los Angeles, CaliforniaAges 18 years+ - NCT05159466Recruiting
Transplant from HIV-positive donors to HIV-positive recipients
This trial studies whether it’s safe and effective for HIV-positive people to receive organ transplants from HIV-positive donors. It focuses on matching HIV treatment before and after transplant and checking for major complications.
Metairie, LouisianaAges 18 years+ - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT05452564RecruitingPhase 2
Baricitinib to help reduce HIV in the brain
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
Atlanta, GeorgiaAges 18–65 - NCT05537935RecruitingPhase 4
Low-dose naltrexone for nerve pain in people with HIV
This trial studies whether a low dose of naltrexone can reduce long-lasting nerve-related pain in adults living with HIV. It may help if your pain has been ongoing and you have stable HIV control.
Atlanta, GeorgiaAges 18–75 - NCT06088277Recruiting
Texting to reduce HIV risk for dental patients
This study tests if daily text messages can help people lower their risk of getting HIV. You'll receive texts for a few months and complete surveys to see if the messages help.
Boston, MassachusettsAges 18 years+ - NCT07476339RecruitingPhase 4
Returning to HIV Care with Biktarvy
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Clearwater, FloridaAges 18 years+ - NCT06139224Recruiting
Gut Bacteria and Inflammation in HIV and Heavy Drinking
This study looks at how gut bacteria and inflammation interact in people with both HIV and heavy alcohol use. It aims to find new ways to improve health by understanding these connections.
Chicago, IllinoisAges 45–75 - NCT06267508Recruiting
HIV testing and treatment for newborns
This study looks at ways to test and treat newborns for HIV early to improve their long-term health. It is for mothers with HIV whose babies are less than 3 days old and who are willing to have their babies tested and followed at home.
BeiraAges 18 years+ - NCT06531772Recruiting
Study of TB and HIV co-infection outcomes
This study looks at the health of people who have both tuberculosis (TB) and HIV. It helps doctors understand how the two infections affect each other and what treatments work best.
AsyutAges Any age - NCT06814275Recruiting
Brain health study for HIV+ stimulant users
This study uses brain scans to understand how stimulant use affects the brain in people with HIV who are on treatment. It may help find ways to improve brain health.
Winston-Salem, North CarolinaAges 18–59 - NCT06819176RecruitingPhase 1
Adding lenacapavir to disrupt HIV reservoirs in suppressed people
This trial tests whether adding a new long-acting drug, lenacapavir, to your current HIV treatment can reduce the hidden HIV that remains in your body even when standard treatment keeps the virus undetectable. The goal is to see if this can lead to better control of HIV over time.
Bethesda, MarylandAges 18–75 - NCT06886971Recruiting
Strategies to help youth with HIV stay virally suppressed
This trial tests a strategy to help young people with HIV keep their virus levels low. It focuses on using a long-acting injectable medication combination (Cabotegravir and Rilpivirine) and requires communication with your HIV doctor.
Baltimore, MarylandAges 12–30 - NCT07030920RecruitingPhase 2
Reducing inflammation in people living with HIV
This trial tests if a drug can lower inflammation in people with HIV who are on effective treatment. It may help reduce the risk of heart disease and other problems related to chronic inflammation.
Montreal, QuebecAges 18 years+ - NCT07044297RecruitingPhase 3
A study of a new long-acting shot to prevent HIV
This study tests an investigational long-acting shot (MK-8527) to prevent HIV. It is for HIV-negative people who are at higher risk through anal sex without condoms, and who have not used other long-acting HIV prevention before.
Birmingham, AlabamaAges 16 years+ - NCT07071623RecruitingPhase 3
A study of an experimental drug to prevent HIV
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
Homabay County, Homa Bay CountyAges 16–30 - NCT07075146RecruitingPhase 3
Comparing two HIV treatments for people with overweight or obesity
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
Mexico CityAges 18–70 - NCT07221123RecruitingPhase 2
Smell and memory training for brain health
This study tests whether smell exercises can improve memory and thinking in people who are worried about their brain health. If you are 40 or older and have mild memory concerns, you may be able to join.
Birmingham, AlabamaAges 40 years+ - NCT07236905Recruiting
HIV testing access for young children in Uganda
This study makes it easier for children in Uganda to get tested for HIV. It helps find kids who haven't been tested recently so they can learn their status and get care if needed.
MbararaAges 1.5 years–5 years
Hear when a new Human Immunodeficiency Virus (HIV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human immunodeficiency virus (hiv) infection?
- Yes. Clin2 currently lists 65 recruiting human immunodeficiency virus (hiv) infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human immunodeficiency virus (hiv) infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human immunodeficiency virus (hiv) infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.